Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lefamulin vs Moxifloxacin in CABP (LEAP 1)
NCT02559310Phase 3Completed
- Sponsor
- Nabriva Therapeutics plc
- Start
- Sep 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of lefamulin in community-acquired bacterial pneumonia (CAP), sponsored by Nabriva Therapeutics plc. Started Sep 2015; status: completed.
02
Drugs
lefamulin
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT02559310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02559310.